Schindler SE, Karikari TK, Ashton NJ, Henson RL, Yarasheski KE, West T, Meyer MR, Kirmess KM, Li Y, Saef B, Moulder KL, Bradford D, Fagan AM, Gordon BA, Benzinger TL, Balls-Berry J, Bateman RJ, Xiong C, Zetterberg H, Blennow K, Morris JC. Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light. Neurology. 2022 Jul 19;99(3):e245-e257. Epub 2022 Apr 21 PubMed.

Recommends

Please login to recommend the paper.

Comments

  1. Another consideration in improving trial diversity is social and structural determinants to health that impact early screening and diagnosis of patients who are historically minoritized. A consideration is the patient's access to appropriate and quality care and ability to receive referrals for ADRD screening and treatment. A key aspect that may impact ADRD diagnosis in patients of color may also relate to discrimination, socioeconomic status, insurance status, educational level, and living environment. I often wonder if we should consider measuring health disparities in the same way that we measure other biomarkers for ADRD.

    View all comments by Joyce Balls-Berry

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

News

  1. Diversity: FDA Guidance and New Data on Incidence/Biomarkers by Race
  2. Blood Tests: Charting the Path to Primary Care
  3. From St. Louis to Boston, Scientists Grapple with Ethnoracial Divide in AD Biomarkers